الرسائل الموجهة للمختصين الصحيين
الرسائل الموجهة للمختصين الصحيين
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Zelboraf® - Vemurafenib | 2014-03-02 | Risk of liver injury reported with Zelboraf®. |
|
| Neupogen® - Filgrastim | 2014-01-26 | Risk of capillary leak syndrome in patients with cancer. |
|
| ZOFRAN® - Ondansetron | 2013-08-29 | Updated information on posology for intravenous use and dose dependant QT interval prolongation. |
|
| Diane-35® - Ethinylestradiol/Cyproterne | 2013-07-22 | Risk of Thromboembolism. |
|
| LARIAM® - Mefloquine | 2013-07-16 | Important Safety Update of Prescribing Information for LARIAM®.
|
|
| MabThera® - Rituximab | 2013-07-16 | The management of hepatitis B reactivation in patients treated with MabThera®. CLICK HERE |
|
| Fenatnyl‐Janssen ® - Fentanyl | 2013-07-14 | Fenatnyl‐Janssen Introduction of New Warning ‐ Serontonin syndrome may occur under co‐administration with serotonergic drugs.
|
|
| DUROGESIC® -Fentanyl | 2013-07-14 | Introduction of New Warning-Serontonin syndrome may occur under co-administration with serotonergic drugs.
|
|
| TASIGNA® - Nilotinib | 2013-07-14 | Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®. |
|
| VOTRIENT® - Pazopanib | 2013-07-14 | Important change to frequency of Serum liver test monitoring for hepatotoxicity.
|
|